Clinical Trials · NCT05361668
Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Crinetics Pharmaceuticals Inc.
- Enrollment
- 36
- Start date
- Apr 2022
- Locations
- 35 sites, 7 countries
- Primary endpoint
- Safety - Incidence of Treatment-emergent Adverse Events (TEAEs)